6 results
We aim to investigate whether pulsatile flow in patients subjected to CPB preserves postoperative microcirculatory perfusion by prevention of a prothrombogenic profile and endothelial activation as are both present under non-pulsatile flow…
The aim of this extension trial is to provide BIBF 1120 treatment for all patients who have completed the 52 weeks treatment period and the follow up period in the phase III placebo controlled parent trial 1199.34, who may have experienced benefit…
The objective of the trial is to confirm efficacy and a favorable benefit-risk ratio for BIBF 1120 in the treatment of IPF at the dose of 150 mg bid compared to placebo.
to offer continuation of BIBF 1020 treatment for patients with IPF who have completed a prior clinical trial with that drug.establish the long term tolerability and safety profile of BIBF 1120 in IPF.
Primary: To demonstrate that high (100%) stimulation of ONS therapy reduces the mean attack frequency (MAF) in MICCH by at least 35% compared to low (30%) stimulation of ONS.Secondary: To evaluate • the rate of responders (>= 50% reduction in…
Main objective:Parts 1, 3, 4, 5 en 6: AMG 160 monotherapy• Evaluate the safety and tolerability of AMG 160 in adult subjects• Part 1 only: Determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)Part 2: AMG 160 in combination…